Clinical Trial: Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes

U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07269197) titled 'Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes' on Nov. 17.

Brief Summary: Metabolic dysfunction-associated steatotic liver disease (MASLD), a condition where fat builds up in the liver, is common in patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors may help improve liver health, but their effects on liver stiffness and fat are not yet well understood. This study aims to clarify these effects.

Therefore, the aims of this study are:

1. Measurement of liver stiffness and liver steatosis using novel ultrasound-based methods before initi...